2 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Withdrawn 2 |
| Phase 2 | 1 | Withdrawn 1 |
Follow CD30-Positive Neoplastic Cells Present: new trials by email Literature Review of CD30-Positive Neoplastic Cells Present trials Research Report on CD30-Positive Neoplastic Cells Present
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides | Phase 1 | Withdrawn | City of Hope Medical Center | 2019-03-01 | 2019-04-30 | |
| Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis - Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present | Phase 1 / Phase 2 | Withdrawn | University of Washington | 2018-01-03 | 2019-10-10 |
Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Sezary Syndrome (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Brentuximab Vedotin (2) · Lenalidomide (1) · ceritinib (1)
City of Hope Medical Center (1) · University of Washington (1)
United States (2)
Andrei Shustov (1) · Jasmine Zain, MD (1)
P30CA015704 (1)